人民财讯12月11日电，阳光诺和(688621)12月11日公告，公司拟以自有资金出资2000万元，认缴弼领生 物新增注册资本8.2661万元，增资完成后将持有其2.0435%的股权。弼领生物成立于2021年5月，是一家 专注于新型纳米偶联药物及精准纳米递送技术研发的生物科技企业，组建了一支覆盖生物、化学、材 料、工程、纳米技术等领域的多学科交叉研发团队。 ...

Core Viewpoint - The company plans to invest 20 million yuan in BiLing Bio to acquire a 2.0435% stake, enhancing its strategic positioning in the nanomedicine sector [1] Group 1: Investment Details - The investment will be made using the company's own funds to subscribe to an increase in registered capital of 82,661 yuan in BiLing Bio [1] - The investment has been approved by the company's general manager office meeting and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Target Company Overview - BiLing Bio focuses on the research and development of novel nano-conjugated drugs and precise nano-delivery technologies [1] - In the previous year, BiLing Bio reported a revenue of 481,100 yuan and a net loss of 40,859,500 yuan [1] Group 3: Strategic Implications - This investment allows the company to enter the nanomedicine market, which is seen as a strategic opportunity [1] - However, the target company may face operational and market risks [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Core Points - The company has completed the deregistration of its subsidiary, Nanjing Nuohua Pharmaceutical Technology Co., Ltd. (Nuohua), as approved by the board on May 12, 2025 [1][2] - The deregistration process was finalized after receiving the registration notice from the Nanjing Jiangbei New District Administrative Approval Bureau [1] - The deregistration will not have a significant impact on the company's overall business development and profitability [2] Summary by Sections - **Deregistration Process** - The board of directors approved the deregistration of Nuohua on May 12, 2025 [1] - The company received the registration notice confirming the completion of the deregistration [1] - **Impact on Financials** - The consolidation scope of the company's financial statements will change, but it will not significantly affect the overall financial statements [2] - There are no adverse effects on the interests of the company and all shareholders, particularly minority shareholders [2]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-107 北京阳光诺和药物研究股份有限公司 关于注销孙公司南京诺和欣医药科技有限公司暨关 联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 5 月 12 日召开第二届董事会第十九次会议，审议通过了《关 于注销孙公司南京诺和欣医药科技有限公司暨关联交易的议案》，同意注销控股 孙公司南京诺和欣医药科技有限公司（以下简称"诺和欣"）。具体内容详见公 司于 2025 年 5 月 13 日在上海证券交易所网站（www.sse.com.cn）披露的《北京 阳光诺和药物研究股份有限公司关于注销孙公司南京诺和欣医药科技有限公司 暨关联交易的公告》（公告编号：2025-042）。 近日，公司收到南京江北新区管理委员会行政审批局出具的《登记通知书》， 对诺和欣的注销登记申请予以登记，注销登记手续已办理完毕。 诺和欣注销完成后，不会对公司整体业务发展和盈利水平产生重大影响，公 司合并财务报表的范围将相应发生变化，但不会对公司合并财务报表产生较大影 ...

Group 1: Financial Performance - 三环集团2025年归母净利润预计为2782百万，增速为27%[1] - 沪电股份2025年归母净利润预计为4042百万，增速为56%[1] - 明阳电气2025年归母净利润预计为789百万，增速为19%[1] Group 2: Revenue Growth - 三环集团2025年营业收入预计为9207百万，增速为25%[1] - 沪电股份2025年营业收入预计为18654百万，增速为40%[1] - 明阳电气2025年营业收入预计为7886百万，增速为22%[1] Group 3: Market Opportunities - AI服务器推动MLCC行业量价齐升，预计整机用量较传统架构提高300%[1] - SOFC技术迭代升级，度电成本已与燃气轮机接近平价，带来放量机会[1] - 牧原股份生猪屠宰量同比增长140%，Q3屠宰肉食业务实现单季度盈利[1]

Group 1 - The main point of the article highlights the net inflow of main funds in the Shanghai and Shenzhen markets, amounting to 10.84 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 320 million yuan [1] - A total of 250 stocks experienced net inflows, while 339 stocks saw net outflows, indicating a mixed sentiment in the market [1] - Among the stocks with significant net inflows, Jinghe Integrated led with a net inflow of 183 million yuan, followed by Wanrun New Energy and Jinpan Technology with inflows of 144 million yuan and 139 million yuan respectively [2] Group 2 - There are 52 stocks that have seen continuous net inflows for more than three trading days, with Sunshine Nuohe leading at eight consecutive days of inflow [2] - Conversely, 127 stocks have experienced continuous net outflows, with Zhimingda showing the longest streak at 19 consecutive days of outflow [2] - The top stocks by net inflow include Jinghe Integrated, Wanrun New Energy, and Jinpan Technology, with respective inflow rates of 8.41%, 10.21%, and 6.80% [2][3]

Core Insights - Sunshine Nuohe announced the signing of a share transfer agreement between its wholly-owned subsidiary Beijing Nuohe Demai Pharmaceutical Technology Co., Ltd. and Beijing Zhongjian Peilian Medical Research Institute, resulting in the transfer of 70% of Shanghai Meisuke Medical Data Co., Ltd. to Zhongjian Peilian for a cash consideration of 2 million yuan [1] - The transaction aims to address the long-term losses of Meisuke Medical Data, enhance asset operation efficiency, reduce management costs, and improve the sustainability of operations [1] Summary by Sections - **Transaction Details** - Nuohe Demai will transfer 70% of its stake in Meisuke Medical Data for 2 million yuan [1] - Nuohe Meichuang will transfer its 30% stake in Meisuke Medical Data for 0 yuan [1] - Post-transaction, Nuohe Demai will no longer hold any equity in Meisuke Medical Data, which will be excluded from the consolidated financial statements [1] - **Rationale for the Transaction** - Meisuke Medical Data has been in a state of long-term losses [1] - The decision is based on a comprehensive assessment of the company's actual situation [1] - The goal is to enhance asset operation efficiency, lower management costs, and strengthen the company's ongoing operational capabilities [1]

Core Points - The clinical trial for Ketoprofen gel patch, aimed at alleviating knee osteoarthritis pain, has been initiated by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd. and Beijing Bai'ao Pharmaceutical Co., Ltd. [1] - The trial is a multicenter, randomized, positive drug and placebo-controlled Phase III study, with a registration number of CTR20254424, first published on November 24, 2025 [1]. - The primary endpoint of the trial is the change in VAS pain score (walking) on day 29 compared to baseline, with secondary endpoints including VAS pain scores on days 15 and 22, as well as modified WOMAC scores [1]. Summary by Sections Clinical Trial Details - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 420 individuals [2]. - The drug is administered as a patch, with a dosage of one patch twice daily for four consecutive weeks [1]. Drug Information - Ketoprofen gel patch is a chemical drug indicated for knee osteoarthritis, characterized by symptoms such as knee pain, swelling, and stiffness [1]. - Diagnosis relies on symptoms, physical examination, and imaging studies like X-rays and CT scans [1]. Evaluation Metrics - The trial will evaluate the efficacy of the drug against placebo and a positive control, as well as assess the safety of the drug [1]. - Key metrics include changes in pain scores and overall functionality as measured by the WOMAC scale [1].

Group 1 - The company will hold its fifth extraordinary general meeting of shareholders on December 12, 2025, at 14:30 [2][48] - The voting will be conducted through the Shanghai Stock Exchange's online voting system, with specific time slots for both online and on-site voting [2][5] - Shareholders must register to attend the meeting, with registration available both in person and via email [12][13] Group 2 - The company announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. from its wholly-owned subsidiary, Beijing Nuohuo Demai Pharmaceutical Technology Co., Ltd., to Beijing Zhongjian Peilian Medical Research Institute [21][40] - The transaction is valued at 2 million yuan, and the subsidiary will no longer hold any equity in Meisuke Data after the transfer [21][40] - The decision to transfer the equity was made to improve asset operation efficiency and reduce management costs, as Meisuke Data has been in a state of continuous loss [25][36] Group 3 - The board of directors approved the equity transfer agreement during the 27th meeting of the second board session held on November 25, 2025 [45][46] - The transaction is not classified as a related party transaction or a major asset restructuring [22][24] - The company will ensure compliance with relevant regulations and disclosure obligations regarding the transaction [42][39]